
Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Dynavax Technologies (DVAX) Well Positioned With Medigen Collaboration on COVID-19 Vaccine Programs - Cowen
-
Cowen Reiterates Outperform Rating on Dynavax Technologies (DVAX) on Medicago Deal
-
Cowen Reiterates Outperform Rating on Dynavax Technologies (DVAX) Following Announced COVID-19 Vaccine Trial
-
Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Dynavax (DVAX) Prices 14M Share Common Offering at $5/Sh
-
Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock
-
Dynavax (DVAX) to Offer Common Stock
-
Dynavax Technologies Announces Proposed Public Offering of Common Stock
-
Dynavax to Present at the Cowen 40th Annual Health Care Conference
-
Dynavax (DVAX) Prices 18.525M Unit Offering at $3/Unit
-
Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
-
Dynavax (DVAX) to Offer up to $60M in Common Stock
-
Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock
-
Pre-Open Movers 05/24: (WKHS) (DECK) (DVAX) Higher; (FL) (ADSK) (DXC) (more...)
-
Dynavax to Present at 39th Annual Cowen Healthcare Conference
-
Dynavax to Present at the Cowen & Co. Annual Health Care Conference
-
Dynavax (DVAX): Heplisav Alone Is Worth $30 - Cowen
-
Dynavax (DVAX) Files to Offer 150M in Common Stock
-
Cowen Positive on Dynavax (DVAX) Into Next Week's Heplisav PDUFA
-
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
-
Dynavax (DVAX) Prices 5M Share Offering at $15/Sh
-
Dynavax Prices Public Offering of Common Stock
-
Dynavax (DVAX) Proposed $125M Public Offering of Common Stock
-
Dynavax Announces Proposed Public Offering of Common Stock
-
Dynavax (DVAX): Heplisav Gets FDA Approval - Cowen
-
Dynavax (DVAX) Heplisav Briefing Docs Largely As Anticipated; Sees 50% Chance of Approval
-
Dynavax to Present at the Cowen and Company 37th Annual Health Care Conference
-
Dynavax (DVAX) VRBPAC Cancellation Implications are More Positive than Negative - Cowen
-
Dynavax to Participate in the Cowen and Company 36th Annual Health Care Conference
-
Dynavax (DVAX) Likely Takeout Candidate Following Positive Phase 3 Data, Says Cowen
-
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
-
Dynavax (DVAX) Prices 4.55M Common Stock Offering at $27.50/Share
-
Dynavax Prices Public Offering of Common Stock
-
Dynavax (DVAX) Announces Common Stock Offering
-
Dynavax Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 7/9: (DVAX) (PG) (SYF) (XOMA)
-
Cowen Lists Top 10 Potential Biotech Surprises Of 2015; Is an Old Fashioned Scandal in the Cards? (GILD) (BIIB) (AEGR) (more...)
-
Dynavax (DVAX) Price Target Adjusted to $60 at Cowen
-
Dynavax Technologies (DVAX) Prices 79.57M Shares of Common at $1.075
-
Dynavax (DVAX) Announces Common, Preferred Stock Offering
-
Notable Analyst Rating Changes 01/02: (WAG) (X) (MAR) Upgraded; (SKUL) (LNKD) (KSS) Downgraded
-
Cowen Starts Dynavax Technologies (DVAX) at Outperform
-
Unusual 11 Mid-Day Movers 6/4: NVAX, WIND, SYMX, OCLS Higher; OMEX, OPTV, ANF, DVAX Lower